Table 1.
Demographic data of clinicopathological characteristics of PCa patients and controls.
Table 2.
Comparisons of NK cell activity, % total NK cell population, distribution of CD56dim and CD56bright subsets, and the CD56dim-to-CD56bright ratio between patients and controls.
Figure 1.
(A) Representative flow cytometric data of the distribution of total NK cell population represented by CD3−CD56+ cells.
(B) Representative flow cytometric data of two major NK cell subsets detected in peripheral blood. Left, upper box: CD16+CD56dim NK cell subset. Right, lower box: CD16−CD56bright NK cell subset.
Figure 2.
(A) Boxplot diagrams showing flow cytometric distribution results of total NK cell population % between controls and patients, grouped according to cancer stage.
No significant differences of total NK population were noted between patients and controls, and within stage groups. (B) Boxplot diagrams showing flow cytometric distribution results of CD56dim and CD56bright subset distributions within total NK cells between controls and patients, grouped according to cancer stage. *p<0.05, **p<0.01 in relation to controls.
Figure 3.
Boxplot diagram comparing NK cell activity between controls and patients grouped according to cancer stage.
**p<0.01 in relation to controls.
Figure 4.
(A) ROC curves comparing the performances of NK cell activity and CD56dim-to-CD56bright ratio measurements.
(AUC = Area Under the Curve). (B) ROC curves comparing the performances of NK cell activity measurement according to PSA grouped as; 4 to 10 ng/ml and greater than 10 ng/ml. (AUC = Area Under the Curve).
Table 3.
Comparisons of sensitivity and specificity of NK cell activity and CD56dim-to-CD56bright ratio to detect PCa.
Table 4.
Correlation of NK cell activity and CD56dim-to-CD56bright ratio between clinicopathological variables.
Table 5.
Comparisons of NK activity and the CD56dim-to-CD56bright ratio between controls and patients grouped according to clinicopathological variables.